Marker Therapeutics Inc (MRKR)

[thelittleguy]

Marker continues to go back-and-forth with the FDA regarding questions about some “reagents” used in the production of Marker’s multiTAA therapies. Marker has already secured an alternate source and the issue now comes down to a matter of whether it will be faster to address the FDA’s questions or to secure an approval from the FDA to use this new supplier. As it stands, it appears the trial could be delayed for “several more months” at most, but there is the potential that the FDA could give them the go-ahead any day now.